-+ 0.00%
-+ 0.00%
-+ 0.00%

CSPC Group announced that the company previously disclosed that it signed a strategic research and development cooperation agreement with AstraZeneca on June 13, 2025 to discover and develop novel oral small molecule drug candidates. The company received a milestone payment of $10 million from AstraZeneca on August 5, 2026 to exercise the licensing option for one of the PCC projects under the terms of the agreement, indicating that related R&D work under the agreement is progressing steadily according to plan.

Zhitongcaijing·08/05/2026 09:57:08
Listen to the news
CSPC Group announced that the company previously disclosed that it signed a strategic research and development cooperation agreement with AstraZeneca on June 13, 2025 to discover and develop novel oral small molecule drug candidates. The company received a milestone payment of $10 million from AstraZeneca on August 5, 2026 to exercise the licensing option for one of the PCC projects under the terms of the agreement, indicating that related R&D work under the agreement is progressing steadily according to plan.